Cost-Utility of Mandibular Advancement Devices in Mitigating Sleepiness and Traffic Accident Risk in Obstructive Sleep Apnea
Objectives: Mandibular advancement devices (MADs) are an effective alternative treatment for obstructive sleep apnea (OSA), improving daytime symptoms and enhancing quality of life. However, evidence on the cost-effectiveness of MAD for OSA treatment remains limited. This study aimed to conduct a cost-utility analysis comparing MAD treatment for OSA to no treatment in Thailand.
Methods: A social perspective was adopted to evaluate the cost-utility of MAD compared to no treatment using a Markov model with a lifetime horizon in OSA patients with excessive daytime sleepiness (EDS). Input parameters were drawn from international and national sources, including published literature, national databases, and local expert consultations. Costs were presented in the United States dollar (USD), and a 3% discount rate was applied to both costs and outcomes, in accordance with Thailand's National HTA Guidelines.
Results: The base case analysis indicated that using MAD resulted in an increase in QALYs by 0.85, with additional costs of 3,308 USD. This resulted in an ICER of 3,891 USD, which is slightly lower than the willingness-to-pay threshold in Thailand, set at 4,526 USD per QALY. MAD was found to be cost-effective, with a probability of cost-effectiveness of 51.9%. Parameters influencing cost-effectiveness were identified and the most sensitive parameters affecting changes in the incremental cost-effectiveness ratio (ICER) were examined through the one-way sensitivity analysis.
Conclusions: MAD therapy appeared marginally cost-effective in Thai settings for OSA patients with EDS. The considerable uncertainty revealed in sensitivity analyses suggests that further research is needed to clarify key parameters and inform decision-making.
1. Kryger Meir, Roth T, Dement WC. Principles and Practice of Sleep Medicine. Philadephia:Saunders;2017.
2. Dempsey JA, Veasey SC, Morgan BJ, O’Donnell CP. Pathophysiology of sleep apnea. Physiol Rev. 2010;90(1):47-112.
3. Morsy NE, Farrag NS, Zaki NFW, Badawy AY, Abdelhafez SA, El-Gilany AH, et al. Obstructive sleep apnea: personal, societal, public health, and legal implications. Rev Environ Health. 2019;34(2):153-69.
4. Karimi M, Eder DN, Eskandari D, Zou D, Hedner JA, Grote L. Impaired vigilance and increased accident rate in public transport operators is associated with sleep disorders. Accid Anal Prev. 2013;51:208-14.
5. Philip P, Sagaspe P, Lagarde E, Leger D, Ohayon MM, Bioulac B, et al. Sleep disorders and accidental risk in a large group of regular registered highway drivers. Sleep Med. 2010;11(10):973-9.
6. Celikhisar H, Ilkhan GD. Association of presence and severity of obstructive sleep apnoea syndrome with accident risk in city bus drivers. J Pak Med Assoc. 2020;70(12(A)):2184-9.
7. Tregear S, Reston J, Schoelles K, Phillips B. Obstructive sleep apnea and risk of motor vehicle crash: systematic review and meta-analysis. J Clin Sleep Med. 2009;5(6):573-81.
8. Zhang T, Chan AH. Sleepiness and the risk of road accidents for professional drivers: a systematic review and metaanalysis of retrospective studies. Saf Sci. 2014;70:180-8.
9. Bioulac S, Micoulaud-Franchi JA, Arnaud M, Sagaspe P, Moore N, Salvo F, et al. Risk of motor vehicle accidents related to sleepiness at the wheel: a systematic review and meta-analysis. Sleep. 2017;40(10): doi: 10.1093/sleep/zsx134.
10. Amra B, Dorali R, Mortazavi S, Golshan M, Farajzadegan Z, Fietze I, et al. Sleep apnea symptoms and accident risk factors in Persian commercial vehicle drivers. Sleep Breath. 2012;16(1):187-91.
11. Howard ME, Desai AV, Grunstein RR, Hukins C, Armstrong JG, Joffe D, et al. Sleepiness, sleep-disordered breathing, and accident risk factors in commercial vehicle drivers. Am J Respir Crit Care Med. 2004;170(9):1014-21.
12. Neruntarat C, Chantapant S. Prevalence of sleep apnea in HRH Princess Maha Chakri Srinthorn Medical Center, Thailand. Sleep Breath. 2011;15(4):641-8.
13. Tregear S, Reston J, Schoelles K, Phillips B. Continuous positive airway pressure reduces risk of motor vehicle crash among drivers with obstructive sleep apnea: systematic review and meta-analysis. Sleep. 2010;33(10):1373-80.
14. Cassel W, Ploch T, Becker C, Dugnus D, Peter JH, Von Wichert P. Risk of traffic accidents in patients with sleep-disordered breathing: Reduction with nasal CPAP. Eur Respir J. 1996;9(12):2606-11.
15. Sawunyavisuth B, Ngamjarus C, Sawanyawisuth K. A meta analysis to identify factors associated with CPAP machine purchasing in patients with obstructive sleep apnea. Biomed Rep. 2022;16(6):1-9.
16. Hoekema A, Stegenga B, Bakker M, Brouwer WH, de Bont LG, Wijkstra PJ, et al. Simulated driving in obstructive sleep apnoea–hypopnoea; effects of oral appliances and continuous positive airway pressure. Sleep Breath. 2007;11(3):129-38.
17. Quinnell TG, Bennett M, Jordan J, Clutterbuck-James AL, Davies MG, Smith IE, et al. A crossover randomized controlled trial of oral mandibular advancement devices for obstructive sleep apnoea-hypopnoea (TOMADO). Thorax. 2014;69(10):938-45.
18. Ramar K, Dort LC, Katz SG, Lettieri CJ, Harrod CG, Thomas SM, et al. Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: an update for 2015: an American academy of sleep medicine and american academy of dental sleep medicine clinical practice guideline. J Clin Sleep Med. 2015;11(7):773-827.
19. Gottlieb DJ, Punjabi NM. Diagnosis and management of obstructive sleep apnea: a review. JAMA. 2020 ;323(14):1389-400.
20. Road Safety Collaboration. ThaiRSC [Internet]. [cited 2022Feb 2]. Available from: https://www.thairsc.com/
21. Transport Statistics Sub-Division PDD of LTT. The Number of Driving Licences and Transport Personnel Licences [Internet]. 2022. Available from: https://web.dlt.go.th/statistics/
22. Luzzi V, Mazur M, Guaragna M, Di Carlo G, Cotticelli L, Magliulo G, et al. Correlations of obstructive sleep apnea syndrome and daytime sleepiness with the risk of car accidents in adult working population: a systematic review and meta-analysis with a gender-based approach. J Clin Med. 2022;11(14):3971.
23. Middleton JW, Dayton A, Walsh J, Rutkowski SB, Leong G, Duong S. Life expectancy after spinal cord injury: a 50-year study. Spinal Cord. 2012;50(11):803-11.
24. Sittimart M, Butani D, Poonsiri C, Korakot M, Nalongsack M, Chalermkitpanit P, et al. Cost-utility analysis of radiofrequency ablation among facet joint-related chronic low back pain patients in Thailand. Pain Physician. 2024 Sep;27(7):E761–73.
25. Uniken Venema JA, Doff MH, Joffe-Sokolova D, Wijkstra PJ, van der Hoeven JH, Stegenga B, et al. Long-term obstructive sleep apnea therapy: a 10-year follow-up of mandibular advancement device and continuous positive airway pressure. J Clin Sleep Med. 2020;16(3):353-9.
26. Riewpaiboon A. Standard Cost List for Health Technology Assessment [Internet]. 2009 [cited 2022 Feb 2]. Available from: costingmenu.hitap.net
27. Pradabboon K, Phanthunane P, Pratoomsoot C. The economic cost of road traffic injuries among people receiving social security benefits. BEC Journal. 2011;9(2):109-23.
28. Thailand Consumer Price Index. Available online: https://www.price.moc.go.th/price/cpi/index_new.as... (accessed on 2 Feb 2022).
29. Thailand Consumer Price Index. Available online: https://www.price.moc.go.th/price/cpi/index_new.as... (accessed on 2 Feb 2022).
30. Sadatsafavi M, Marra CA, Ayas NT, Stradling J, Fleetham J. Cost-effectiveness of oral appliances in the treatment of obstructive sleep apnoea–hypopnoea. Sleep Breath. 2009;13:241-52.
31. Jenkinson C, Petersen S, Stradling J. How should we evaluate health status? a comparison of three methods in patients presenting with obstructive sleep apnoea. Qual Life Res. 1998;7:95-100.
32. Currie CJ, McEwan P, Peters JR, Patel TC, Dixon S. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health. 2005;8(5):581-90.
33. Graham JD, Thompson KM, Goldie SJ, Segui-Gomez M, Weinstein MC. The cost-effectiveness of air bags by seating position. JAMA. 1997;278(17):1418-25.
34. Banhiran W, Assanasen P, Nopmaneejumrudlers C, Nujchanart N, Srechareon W, Chongkolwatana C, et al. Adjustable thermoplastic oral appliance versus positive airway pressure for obstructive sleep apnea. Laryngoscope. 2018;128(2):516-22.
35. Sharples L, Glover M, Clutterbuck-James A, Bennett M, Jordan J, Chadwick R, et al. Clinical effectiveness and cost-effectiveness results from the randomised controlled Trial of Oral Mandibular Advancement Devices for Obstructive sleep apnoea-hypopnoea (TOMADO) and long-term economic analysis of oral devices and continuous positive airway pressure. Health Technol Assess. 2014;18(67):1-296.
36. Chaikledkaew U, Kittrongsiri K. Guidelines for health technology assessment in Thailand (second edition)-the development process. J Med Assoc Thai. 2014;97(Suppl 5):S4-9.
37. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: OUP; 2006.
38. Van Haesendonck G, Dieltjens M, Kastoer C, Shivalkar B, Vrints C, Van De Heyning CM, et al. Cardiovascular benefits of oral appliance therapy in obstructive sleep apnea: a systematic review. J Dent Sleep Med. 2015;2(1):9-14.
39. Ou YH, Colpani JT, Chan SP, Loke W, Cheong CS, Kong W, et al. Mandibular advancement device versus CPAP in lowering 24-hour blood pressure in patients with obstructive sleep apnoea and hypertension: the CRESCENT trial protocol. BMJ Open. 2023;13(5):e072853.
40. Ou YH, Colpani JT, Cheong CS, Loke W, Thant A tar, Shih EC, et al. Mandibular advancement vs CPAP for blood pressure reduction in patients with obstructive sleep apnea. J Am Coll Cardiol. 2024;83(18):1760-72.
41. McDaid C, Griffin S, Weatherly H, Duree K, Van der Burgt M, Van Hout S, et al. Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea-hypopnoea syndrome: a systematic review and economic analysis. Health Technol Assess. 2009; 13(4): doi: 10.3310/hta13040.
42. Giannopoulou A, Burgers LT, van Bruggen MP, de Vries N, Redekop WK, Rijnsburger A. Economic evaluation of mandibular advancement device to treat obstructive sleep apnea. Value Health. 2013;16(7):A373.
43. Poullié AI, Cognet M, Gauthier A, Clementz M, Druais S, Späth HM, et al. Cost-effectiveness of treatments for mild-to-moderate obstructive sleep apnea in France. Int J Technol Assess Health Care. 2016;32(1-2):37-45.
44. Andre F, AJ HA, Nurit F, Najib A, Ismail L. The public health burden of obstructive sleep apnea. Sleep Sci. 2021;14(3):257–65.